Akèy › Maladi Alzheimer › Tennessee
Etid klinik pou Maladi Alzheimer nan Tennessee
16 etid pou Maladi Alzheimer ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
- K2 Medical Research, Nashville
Ap rekriteFaz 2
Laj 55 a 85 · Tout sèks · Mizajou Sep 28, 2026 · NCT07794670A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
- Neurology Clinic, P.C., Cordova
Ap rekriteFaz 4
Laj 50 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07633470A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Vanderbilt Psychiatric Hospital, Nashville
Ap rekriteFaz 3
Laj 55 a 90 · Tout sèks · Mizajou Sep 22, 2026 · NCT06585787Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
- K2 Medical Research Nashville LLC, Nashville
Ap rekriteFaz 2
Laj 55 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06847321Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Genesis Neuroscience Clinic, Knoxville
- K2 Medical Research - Nashville, Nashville
Ap rekriteFaz 3
Laj 50 a 90 · Tout sèks · Mizajou Sep 21, 2026 · NCT07177352A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
- Neurology Clinic - Cordova /ID# 277790, Cordova
Ap rekriteFaz 1/2
Laj 50 a 90 · Tout sèks · Mizajou Sep 18, 2026 · NCT07599670Alzheimer's Tau Platform: Master Protocol
- Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 2
Laj 50 a 80 · Tout sèks · Mizajou Sep 8, 2026 · NCT06957418Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- Local Institution - 0031, Chattanooga
- Neurology Clinic, P.C., Cordova
- Vanderbilt University Medical Center- Village, Nashville
Ap rekriteFaz 2
Laj 55 a 90 · Tout sèks · Mizajou Sep 1, 2026 · NCT06808984A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Neurology Clinic, P.C., Cordova
Ap rekriteFaz 3
Laj 60 a 85 · Tout sèks · Mizajou Aug 20, 2026 · NCT06976216A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
- Neurology Clinical, P.C., Cordova
Ap rekriteFaz 1/2
Laj 35 a 85 · Tout sèks · Mizajou Jul 10, 2026 · NCT05462106Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition
- Vanderbilt University Medical Center Clinical Research Center, Nashville
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 a 55 · Tout sèks · Mizajou Jun 22, 2026 · NCT05231798Trial-Ready Cohort-Down Syndrome (TRC-DS)
- Vanderbilt University Medical Center Center for Cognitive Medicine, Nashville
Ap rekriteEtid obsèvasyon
Laj 25 a 55 · Tout sèks · Mizajou May 18, 2026 · NCT04165109Swallowing Impairments in Adults With and Without Alzheimer's Disease
- Vanderbilt University Medical Center, Nashville
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 60 ak plis · Tout sèks · Mizajou May 8, 2026 · NCT06678100Tennessee Alzheimer's Project
- Vanderbilt University Medical Center, Nashville
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 60 ak plis · Tout sèks · Mizajou Feb 5, 2026 · NCT05372172Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
- Cumberland Medical Center, Crossville
- Roane Medical Center, Harriman
- Fort Sanders Regional Medical Center, Knoxville
- ak 3 plis
Ap rekrite
Laj 60 a 90 · Tout sèks · Mizajou Oct 29, 2025 · NCT07222280Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
- National HealthCare Corporation, Murfreesboro
Ap rekrite
Laj 50 ak plis · Tout sèks · Mizajou Mar 12, 2024 · NCT05820919Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.